RECLAST (zoledronic acid)

Effective Date: 1/28/14
Date Developed: 1.28.14 by Robert Sterling, MD
Last Approval Date: 01.26.16, 01.24.17

RECLAST is a bisphosphonic acid which inhibits osteoclastic bone resorption

Authorization:  Treatment and prevention of osteoporosis in women in patients with GI intolerance to oral bisphosphonates; osteoporosis in men; glucocorticoid-induced osteoporosis in men or women*; Paget’s disease of bone**

Unlabeled Uses: prevention of bone loss associated with aromatase inhibitor therapy in postmenopausal women with breast cancer; prevention of bone loss associated with androgen deprivation therapy in prostate cancer. (See VCHCP policy on Coverage of Prescription Medication of Off-Label Use.)

Dosing:  5 mg infusion (over no less than 15 minutes) once a year; earlier re-treatment may be considered in patients with Paget’s disease who have clinically relapsed

PRECAUTIONS:  Treat pre-existing hypocalcemia and treat patients with calcium (1200 mg) and vitamin D (800 IU) supplementation; contraindicated in patients with renal failure (Ccr<35mL/min); osteonecrosis of the jaw (ONJ) after tooth extraction or dental abscess and atypical femoral fractures may occur (rare); musculoskeletal pain; acute transient inflammatory response at initiation of therapy; contraindicated in pregnancy

DRUG INTERACTIONS:  Increased risk of GI ulcers and renal toxicity of NSAIDs; PPIs may decrease effectiveness; aminoglycoside and loop diuretics may increase the risk of hypocalcemia;

* in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months
** with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal

REFERENCES


Revision History:
Date Reviewed/No Updates: 01.13.15 by C. Sanders, MD
Date Approved by P&T Committee: 01.27.15
Date Reviewed/No Updates: 01.26.16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.26.16
Date Reviewed/No Updates: 01.24.17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.24.17

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>